Psychedelics for treating psychiatric disorders: Are they safe?
Current Psychiatry December 1, 2022 Madonna Thakur 3 citations
Psychedelics, including psilocybin, LSD, DMT/ayahuasca, MDMA, and ketamine, are being investigated as treatments for depression, PTSD, and substance use disorders, often within psychedelic-assisted psychotherapy. Although generally well-tolerated, these substances have been linked to various adverse effects. The article reviews the safety profiles of both classical and nonclassical psychedelics, noting that ketamine is already used for depression and FDA approval is anticipated for other psychedelics.